Arvinas (ARVN)
(Delayed Data from NSDQ)
$24.36 USD
+0.70 (2.96%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $24.38 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 101 - 120 ( 213 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Poised to Build a Robust Prostrate Cancer Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Exciting Deal Likely to Accelerate Expanding Pipeline of PROTACs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Looking Beyond Pfizer Collaboration; Reit Buy and Raising PT to $135
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Enters $2B Collaboration With Pfizer for ARV-471 in Breast Cancer
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Pfizer in to Co-develop and Commercialize ?471; PT to $113
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Virtual Marketing by Analyst Zegbeh Jallah Begins @ 12pm ET Tomorrow
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Key Clinical Data Updates Ahead in 2H
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Lead Clinical Trial Programs Pursing Best-in-Class Potential and Accelerated Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update- Strong Execution with Multiple Catalysts Reaffirmed for 2H21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from 2021 AACR Virtual Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Expected to Build on Clinical Successes in 2021; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A